DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Urticaria | Treatment Algorithms: Claims Data Analysis | Chronic spontaneous urticaria | US | 2023
The drug market for chronic spontaneous urticaria (CSU; previously known as chronic idiopathic urticaria) is dominated by oral medications, including those approved (e.g., first- and second-…
Acute Coronary Syndrome: Secondary Prevention | Treatment Algorithms: Claims Data Analysis | US | 2025
Acute coronary syndrome (ACS)—subtype of coronary artery disease (CAD)—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable…
Alzheimer’s Disease – Special Topics – Special Topics: Caregiver Perspectives on Diagnostics and Leqembi in the Treatment of Alzheimer’s Disease (US)
Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS…
Major Depressive Disorder | Treatment Algorithms: Claims Data Analysis | US | 2024
Major depressive disorder (MDD) is a highly drug-treated condition that uses an array of drug classes, including, but not limited to, selective serotonin reuptake inhibitors (SSRIs), selective…
Primary Biliary Cholangitis | Treatment Algorithms: Claims Data Analysis | US | 2024
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and, ultimately, destruction of the interlobular bile ducts; this process is…
Acute Musculoskeletal Pain – Epidemiology – Epidemiology – Acute Musculoskeletal Pain – Mature markets
Clarivate Epidemiology’s coverage of acute musculoskeletal pain (AMP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States…
